Visual Impairment News and Research

Latest Visual Impairment News and Research

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare.

3 Mar 2014

Photoreactive compounds open new routes to treatment of neurological diseases

Photoreactive compounds developed by scientists of Ludwig-Maximilians-Universitaet (LMU) in Munich directly modulate nerve-cell function, and open new routes to the treatment of neurological diseases, including chronic pain and certain types of visual impairment.

3 Mar 2014

Study establishes innovative approaches to improve vision of young children with brain tumor

Robert Avery, DO, MSCE, of Children's National Health System and colleagues are establishing innovative approaches with technology and medication to improve the vision of young children who have visual pathway glioma, a type of brain tumor.

3 Mar 2014

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme.

10 Feb 2014

Moderate aerobic exercise helps preserve nerve cells in retina after damage

Moderate aerobic exercise helps to preserve the structure and function of nerve cells in the retina after damage, according to an animal study appearing February 12 in The Journal of Neuroscience. The findings suggest exercise may be able to slow the progression of retinal degenerative diseases.

9 Feb 2014

Study: Probability of blindness due to glaucoma has decreased by nearly half

The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.

21 Jan 2014

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients.

16 Jan 2014

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients. With this new knowledge, investigators aim to accelerate the process of healing and repair in damaged corneas to ultimately reverse the effects of diabetes-induced eye complications.

15 Jan 2014

No added benefit from aflibercept, shows study

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.

8 Jan 2014

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.

6 Jan 2014

People with diabetes at risk of developing diabetic macular edema during their lifetime

Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the disease and visual impairment, and only six in 10 had their eyes fully examined in the year leading up to the study.

20 Dec 2013

Researchers investigate several non-invasive methods for measuring intracranial pressure

Do you ever turn your world upside down by standing on your head? After a few minutes you might feel some pressure in your face and around your skull. This is because headstands invert the body's blood flow, pushing more blood toward your head.

19 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Exposure to high-powered blue handheld laser devices can cause serious eye injuries

Exposure for even fractions of a second to high-powered blue handheld laser devices can cause serious eye injuries, according to a study recently released online in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers have concluded that the wide availability of these devices, which are often marketed as toys, could lead to an epidemic of ocular injuries, and greater public awareness and government intervention should be encouraged.

6 Dec 2013

Visual Impairment News and Research

Latest Visual Impairment News and Research

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Photoreactive compounds open new routes to treatment of neurological diseases

Study establishes innovative approaches to improve vision of young children with brain tumor

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

Moderate aerobic exercise helps preserve nerve cells in retina after damage

Study: Probability of blindness due to glaucoma has decreased by nearly half

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

No added benefit from aflibercept, shows study

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

People with diabetes at risk of developing diabetic macular edema during their lifetime

Researchers investigate several non-invasive methods for measuring intracranial pressure

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Exposure to high-powered blue handheld laser devices can cause serious eye injuries

Study finds way to regulate sleep patterns of children with brain disorders

Auditory processing disorder diagnosis: an interview with Dr Doris-Eva Bamiou, UCL Ear Institute

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Nurse educator receives 2013 ARN Educator Role Award at 39th Annual ARN Educational Conference

Black women with vitamin D deficiency during pregnancy more likely to deliver preterm babies

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Visual Impairment News and Research

Latest Visual Impairment News and Research

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Newsletters you may be interested in